T1	Participants 657 719	patients undergoing standard versus extended lymphadenectomy i
T2	Participants 721 752	radical PD for pancreatic cance
T3	Participants 792 852	112 patients with potentially curable pancreatic head cancer
T4	Participants 1470 1517	patients with resectable pancreatic head cancer
T5	Participants 1011 1060	A hundred and one eligible patients were analyzed
